Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Syros Pharmaceuticals
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 16, 2022
Details:
In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s pipeline including SM-88 (D/L-alpha-metyrosine).
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Syros Pharmaceuticals
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Merger July 05, 2022
Details:
The results that SM-88 alone showed antiproliferative effects in each of the sensitive and resistant cells lines, and that the combination of SM-88 and MPS had an additive effect in these models.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
SM-88 (D/L-alpha-metyrosine), with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2022
Details:
SM-88 is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
The study demonstrated that SM-88 had promising efficacy and safety outcomes for prostate cancer patients while sparing testosterone. The study also demonstrated a reduction of CTCs that may prove to be a better surrogate for patient outcomes than PSA, particularly for SM-88.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity to the treated cells. Previous preclinical research has also shown select bile acids like TYME-19 have had broad antiviral activity.
Lead Product(s): Bile Salts
Therapeutic Area: Infections and Infectious Diseases Product Name: TYME-19
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
The interim futility review of company's HopES Sarcoma Phase II clinical trial for SM-88 was completed in late July and, based on the analysis of the data and recommendations of Dr. Sant Chawla, the study will proceed with the current trial design as planned.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
SM-88 has demonstrated encouraging tumor responses in 15 different cancers across four separate studies with minimal serious grade 3 or higher adverse events .
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer.
Lead Product(s): Methyltyrosine,Methoxsalen,Phenytoin
Therapeutic Area: Oncology Product Name: SM-88
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020